DBVE-PC regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: ABVE-PC Regimen; Adriamycin-Bleomycin-Vincristine-Etoposide/Prednisone-Cyclophosphamide Regimen; DBVE-PC; POG 9245 Regimen
Overview
DBVE-PC regimen refers to a regimen consisting of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide, given in combination with radiation therapy and used for the treatment of high-risk, childhood Hodgkin’s lymphoma.[1][2]
Regimen
DDoxorubicin
BBleomycin
VVincristine
EEtoposide
PPrednisone
CCyclophosphamide
Indications
- High-risk, childhood Hodgkin’s lymphoma[3]
References
- ↑ “NCI Thesaurus”.
- ↑ “R-CHOP – National Cancer Institute”.
- ↑ Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R; et al. (2009). “A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425”. Blood. 114 (10): 2051–9. doi:10.1182/blood-2008-10-184143. PMC 2744567. PMID 19584400.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
